Sleep disturbances and restless legs syndrome in postmenopausal women with early breast cancer given adjuvant aromatase inhibitor therapy

• DOI: 10.1016/j.breast.2022.10.006
• Publication Date: 2022-10-18T03:58:06Z
• Authors: Rebecca Pedersini; Pierluigi di Mauro; Vito Amoroso; Vincenza Castronovo; Manuel Zamparini; Sara Monteverdi; Lara Laini; Greta Schivardi; Deborah Cosentini; Salvatore Grisanti; Sara Marelli; Luigi Ferini Strambi; Alfredo Berruti
• Keywords: Restless Legs Syndrome; Depression; Adjuvant Therapy; Sleep

Whether adjuvant therapy with aromatase inhibitors (AIs) causes sleep disturbances or not in postmenopausal women early breast cancer (EBC) is still a controversial issue.Between March 2014 and November 2017, validated questionnaires for assessing insomnia, anxiety, depression, quality of life (QoL) restless legs syndrome (RLS) were administered to 160 EBC patients at baseline after 3, 6, 12, 24 months AI therapy.AI significantly decreased the patients' QoL, but did influence anxiety depression. However, it increased frequency severity RLS. Patients RLS (19%) who developed during (26.3%) reported statistically lower sleep, higher worse QoL compared never (54.7%).Although does affect quality, may increase frequency. The presence could identify group benefit from psychological support.